Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

Inclusion Criteria:

• Participants must have met eligibility criteria at screening and baseline in theparent trial (DELTA 1 or DELTA 2).

• Participants must have completed the treatment period in the parent trial (to beassessed at baseline visit in this extension trial).

• Participants must have complied with the clinical trial protocol in the parent trialto the satisfaction of the investigator.

• A woman of childbearing potential must use an acceptable method of birth controlthroughout the trial up until the end-of-treatment/early termination visit.

Exclusion Criteria:

• Participants who prematurely discontinued treatment with IMP or initiated rescuemedication in the parent trial.

• Participants who experienced any adverse event (AE) during participation in theparent trial, which precludes further treatment with delgocitinib cream 20 mg/g inthe judgement of the investigator.

• Any medical or psychiatric condition that could put the participant at undue risk byparticipating in the trial, or which, by the investigator's judgment, makes theparticipant inappropriate for the trial.